Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder

Value in Health

Volumn 8, Issue 4, 2005, Pages 471-478

  Gianfrancesco, Frank ^a   Wang, Ruey Hua ^a   Pesa, Jacqueline ^b  

^a HECON Associates Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bipolar disorder; Dosing; Quetiapine; Resource use; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MONOTHERAPY; PRIORITY JOURNAL; SCHIZOPHRENIA; ECONOMICS; HEALTH CARE COST; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH CARE COSTS; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MENTAL HEALTH SERVICES; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 24944504519     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.00038.x     Document Type: Article

References (22)

1. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63 (Suppl. 13):S5-11.
2. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US Seroquel Study Group. J Clin Psychopharmacol 1996;16:158-69.
3. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;10: 649-57.
4. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical application in schizophrenia. Exp Opin Pharmacother 2000;1:783-801.
5. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther 2002;2:209-22.
6. Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004;20:619-26.
7. Kapur S, Zipursky R, Jones C, et al. A positron remission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch General Psychiatry 2000;57:553-9.
8. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20.
9. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999;60(Suppl. 9):21-8.
10. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
11. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53:239-48.
12. Pierre JM, Wirshing DA, Cannell J, et al. High dose quetiapine in treatment refractory schizophrenia [Abstract]. Schizophr Res 2003;60(Suppl. 1):299.
13. PharMetrics, Inc. Watertown, Mass. The PharMetrics patient-centric claims database represents 80 health plan contributors and 55 million covered lives.
14. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997;10:63-72.
15. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000;34:200-7.
16. Hosmer DW. Applied Logistical Regression. New York: John Wiley & Sons, 1989.
17. Margolese HC, Chouinard G, Beauclaire L, Bélanger MC. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002;22:347-52.
18. Nelson MW, Reynolds R, Kelly DL, et al. Safety and tolerability of high dose quetiapine in treatment refractory schizophrenia: preliminary results from an open-label trial [Abstract]. Schizophr Res 2003;60(Suppl. 1):363.
19. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;16:(Suppl. 2):1-56.
20. Gianfrancesco F, Wang R, Mahmoud R, White R. Methods for claims-based pharmacoeconomic studies in psychosis. Phamacoeconomics 2002;20: 499-511.
21. Zhou XH, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med 1997;127: 752-6.
22. Desgagné A, Castilloux A-M, Angers J-F, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13:487-97.